Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that...
3 transactions — including 0 buys declared by Structure Therapeutics Inc. executives to SEC / AMF / BaFin.
17 institutional funds report a position on GPCR in their latest SEC quarterly filing.
15 recent articles on GPCR.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Automatic detection when 3+ executives buy the same stock simultaneously — historically the most reliable signal.
Berkshire (Buffett), Pershing Square (Ackman), Tiger Global, Bridgewater + 200 more. Who buys what, each quarter.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot small caps whose retail interest explodes before the rest of the market. 100+ tickers monitored.
Create your watchlist and receive every morning at 8am the Brief of events on YOUR tickers.
This public page only shows a preview. The full analysis of GPCR on the Kairos Insider dashboard includes:
Free signup · Premium €29/month no commitment